Next, to investigate whether GINS1 might affect the sensitivity of DLBCL cells to doxorubicin, an important component in the R-CHOP regimen, two DOX-resistant cell lines, FARAGE/DOX and SU-DHL-2/DOX, were induced. The gene discussed is GINS1; the disease is diffuse large B-cell lymphoma.